No, nasal epinephrine is not yet equivalent to IM epinephrine for anaphylaxis treatment
Intramuscular epinephrine remains the standard of care for anaphylaxis, and there is currently insufficient clinical evidence to support nasal epinephrine as an equivalent alternative. 1, 2
Current Standard of Care
The 2020 American Heart Association guidelines unequivocally state that epinephrine should be administered early by intramuscular injection to all patients with signs of systemic allergic reaction, especially hypotension, airway swelling, or difficulty breathing 1. The recommended dose is 0.2 to 0.5 mg (1:1000) intramuscularly into the lateral thigh (vastus lateralis), repeated every 5 to 15 minutes as needed.
Emerging Nasal Formulations: Promise vs. Reality
While several intranasal epinephrine formulations are under investigation, the clinical evidence remains limited:
Pharmacokinetic Studies Show Mixed Results
FMXIN002 (4.0 mg nasal spray): In a 2025 study, 91% of subjects achieved therapeutic plasma levels (100 pg/mL) at 6 minutes versus 55% with IM autoinjector, with faster absorption 3
13.2 mg nasal spray: Multiple 2024 studies showed this formulation achieved plasma levels greater than or comparable to 0.3 mg IM autoinjector, with similar pharmacodynamic effects on blood pressure and heart rate 4, 5
Lower dose formulations (1-5 mg): A 2022 study found 5 mg intranasal epinephrine achieved only 0.5-fold the systemic absorption of 0.3 mg IM, with high variability 6
Critical Gap: No Real-World Clinical Efficacy Data
The fundamental problem is that all existing studies were conducted in healthy volunteers, not patients experiencing actual anaphylaxis 7. A 2026 systematic review concluded that "there is insufficient evidence to determine whether intranasal epinephrine is as effective as intramuscular epinephrine in anaphylaxis" 7.
The available clinical case series consist primarily of conference abstracts without peer-reviewed validation of outcomes in true anaphylactic emergencies 7.
Why This Matters for Mortality and Morbidity
Anaphylaxis kills approximately 200 Americans annually, with fatalities typically resulting from delayed epinephrine administration and severe respiratory or cardiovascular complications 1, 8. The 2005 practice parameter emphasizes that "there is no absolute contraindication to epinephrine administration in anaphylaxis" and that "no data support the use of epinephrine in anaphylaxis through a nonparenteral route" for standard care 8.
Common Pitfalls to Avoid
- Do not substitute nasal epinephrine for IM epinephrine in clinical practice based on pharmacokinetic studies alone
- Do not delay IM epinephrine while attempting alternative routes
- Do not assume faster absorption equals better clinical outcomes - the relationship between plasma levels and symptom resolution in actual anaphylaxis remains unproven
The Bottom Line for Clinical Practice
Until adequately powered clinical trials demonstrate equivalent or superior outcomes (survival, symptom resolution, prevention of biphasic reactions) in patients with actual anaphylaxis, intramuscular epinephrine into the lateral thigh remains the only evidence-based first-line treatment 9, 1, 2, 10.
Alternative routes like inhaled or sublingual epinephrine have been "anecdotally successful" in specific circumstances (e.g., inhaled for laryngeal edema when IV access unavailable), but these remain rescue measures, not standard therapy 8.